Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
ACETYLSALICYLIC ACID
Chanelle Medical
300 mg Milligram
Tablets
1998-09-16
PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Aspirin (Acetylsalicylic acid) Tablets 300 mg 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 300mg of Aspirin (also known as acetylsalicylic acid) For excipients, see 6.1 3 PHARMACEUTICAL FORM Tablet White, circular, biconvex plain tablet. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For the relief of mild to moderate pain in headaches, toothache and neuralgia. For reduction of temperature. For reduction of inflammation in lumbago. 4.2 POSOLOGY AND METHOD OF ADMINSTRATION Adults only: 300mg to 600mg three to four times daily. Do not give to children or adolescents aged under 16 years, except on medical advice, where the benefit outweighs the risk. Elderly: Non steroidal anti-inflammatory drugs should be used with particular caution in elderly patients who are more prone to adverse events. The lowest dose compatible with adequate clinical control should be employed. See also section 4.4. Route of administration Oral. 4.3 CONTRAINDICATIONS Hypersensitivity to any of the ingredients or to other non-steroidal anti-flammatory drugs. Not to be taken by children under 12 years, unless on medical advice. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Issued 02/09/2005_ _CRN 2014464_ _page number: 1_ 4.4 SPECIAL WARNINGS AND SPECIAL PRECAUTIONS FOR USE i) Aspirin may precipitate bronchospasm and induce attacks of asthma or hypersensitivity in susceptible subjects. ii) If the person is taking any other medicine or is under doctor’s care, he should consult the physician before using aspirin. iii) Prolonged use except under medical direction may be harmful. iv) Interference with laboratory tests: Salicylates may produce falsely increased results for blood creatinine, urate ( Read the complete document